Dianthus Therapeutics (DNTH) Enterprise Value: 2017-2025
Historic Enterprise Value for Dianthus Therapeutics (DNTH) over the last 8 years, with Sep 2025 value amounting to $864.0 million.
- Dianthus Therapeutics' Enterprise Value rose 65.33% to $864.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.1 million, marking a year-over-year increase of 117.52%. This contributed to the annual value of $370.0 million for FY2024, which is 1986.34% up from last year.
- Latest data reveals that Dianthus Therapeutics reported Enterprise Value of $864.0 million as of Q3 2025, which was up 152.81% from $341.8 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Enterprise Value ranged from a high of $864.0 million in Q3 2025 and a low of -$138.0 million during Q3 2023.
- For the 3-year period, Dianthus Therapeutics' Enterprise Value averaged around $286.2 million, with its median value being $341.8 million (2025).
- Its Enterprise Value has fluctuated over the past 5 years, first slumped by 497.54% in 2023, then soared by 10,799.76% in 2024.
- Over the past 4 years, Dianthus Therapeutics' Enterprise Value (Quarterly) stood at -$51.6 million in 2022, then soared by 61.97% to -$19.6 million in 2023, then surged by 1,986.34% to $370.0 million in 2024, then skyrocketed by 65.33% to $864.0 million in 2025.
- Its Enterprise Value was $864.0 million in Q3 2025, compared to $341.8 million in Q2 2025 and $319.5 million in Q1 2025.